POEMS Syndrome Market Size, Share, Industry, Forecast and outlook (2024-2031)

POEMS Syndrome Market is Segmented By Diagnosis Type(Electromyelogram (EMG)Blood and/or urine tests imaging(X-ray, CT scan, Others)Physical exam, Biopsy, Others), By Treatment Type(Chemotherapy, Radiation therapy, Physical therapy, Others), By End-User(Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Others), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), 2024-2031.

POEMS Syndrome Market is growing at a high CAGR during the forecast period (2024-2031).

POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) syndrome is a blood disorder that affects several body systems. Abnormal plasma cells produce excessive quantities of antibody proteins to collect in the blood in this uncommon illness. A high concentration of these proteins in the blood can harm nerves and cause organ systems to malfunction. POEMS syndrome does not have conventional treatment. Radiation therapy, chemotherapy, and hematopoietic cell transplantation are alternatives for people with POEMS syndrome.

As per DataM Intelligence, POEMS Syndrome Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global POEMS Syndrome Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. POEMS Syndrome Market in the United States and Canada produces the utmost share. Whereas the European POEMS Syndrome Market is projected to continue its presence globally during the period of 2024-2031.

POEMS Syndrome Market Dynamics

Innovation in the treatment of POEMS Syndrome is expected to drive market growth.

POEMS treatment, like multiple myeloma treatment, aims to eradicate the offending plasma cell clone. High-dose melphalan followed by autologous hematopoietic cell transplant (HCT) provides the best long-term results for eligible individuals. Moreover, patients who cannot tolerate HCT are given plasma cell-directed treatment. Immunomodulatory medicines in various combinations include lenalidomide, proteasome inhibitors like bortezomib, dexamethasone, and cyclophosphamide. Therefore, it has increased the demand for the drug. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Lack of awareness of the disease among the population, side effects of the drugs and restricted access to necessary healthcare facilities are some factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The pandemic's management had an indirect impact on major diseases. In reality, fear of the epidemic's catastrophe is causing many sufferers to put off seeking treatment. Aside from chronic patient monitoring, the practitioner's primary goal is to detect emergency circumstances. The POEMS syndrome with plasmacytoma lytic bone lesion is still a rare occurrence. Radiotherapy is advised as a treatment strategy with variable success in patients with less than three isolated bone plasmacytomas.

In contrast, there is a delay in treating POEMS Syndrome as there is contact between the patient and the doctor. Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

POEMS Syndrome Market Segment Analysis

Chemotherapy segment is expected to hold the largest market share in POEMS syndrome market

The chemotherapy segment is expected to dominate in 2021. The segment is benefited because high-dose chemotherapy with ASCT can achieve excellent clinical responses, with a significant improvement of neuropathy, complete hematologic response (CRH) in 60% of POEMS syndrome patients, and complete VEGF response (CRV) in 50%. For instance, Melphalan is an alkylation agent commonly used to treat plasma diseases such as myeloma and amyloidosis. MDex (Melphalan plus dexamethasone) produced a 100% neurological response. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

POEMS Syndrome Market Overview

POEMS Syndrome Market Geographical Analysis

North America region holds the largest market share in the global POEMS syndrome market

In 2021, North America accounted for the highest revenue share. The advancement in the diagnosis of the disease, well-established clinical facilities, and clinical trials conducted for the treatment and product launches by the market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, Patients with POEMS usually have a long-term, progressively deteriorating, length-dependent, and demyelinating peripheral neuropathy. While the syndrome is comparable to the more frequent CIDP, it differs in several ways. POEMS patients had more axonal degeneration, neuropathic pain, and lower-limb atrophy than CIDP patients, although cranial nerve involvement and dysautonomia are significantly less common. A crucial screening technique for diagnosing POEMS syndrome is serum or urine immunofixation electrophoresis. The symptoms listed above, along with a lambda light chain-restricted immunofixation electrophoresis profile, strongly imply a diagnosis.

Additionally, Geneyork Pharmaceutical, a privately held specialty pharmaceutical company that develops, contract manufactures, and sells finished pharmaceutical products, launched the commercial shipment of Generic Deltasone (Prednisone) Tablets in the United States on February 2, 2020, in collaboration with Lannett Company, Geneyork's U.S. distribution and marketing partner. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

POEMS Syndrome Market Competitive Landscape

Major key players in the POEMS syndrome market are Pfizer, Inc., Bristol-Myers Squibb Company, Baxter, Genentech USA, Inc., Takeda Pharmaceuticals U.S.A., Inc., Oncopeptides AB. Acrotech Biopharma, LLC., LGM PHARMA , Jubilant Cadista Pharmaceuticals Inc.                 

Bristol-Myers Squibb Company:

Overview:

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company. It is headquartered in New York City. The company has advancements in oncology, hematology, immunology and cardiovascular disease. It is dedicated to helping patients prevail over serious diseases through its diverse and promising pipelines and new scientific platforms. Bristol Myers Squibb is at the forefront of oncology with an extensive portfolio of investigational compounds and approved medicines. Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs is a subsidiary of Bristol Myers Squibb.

­Product Portfolio:

REVLIMID (lenalidomide): Lenalidomide is an effective therapy against malignant plasma cells and a potent agent against proinflammatory and proangiogenic cytokines.